Constipation News and Research

Latest Constipation News and Research

Researchers explore key factors to improve astronauts’ nutrition needs during space missions

Centuries ago, ships often sailed with crews numbering in the hundreds returning with tens. Cause of death: Scurvy - a severe depletion of Vitamin C.

4 Aug 2015

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

3 Aug 2015

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

New guidelines for nutrition of management GI symptoms in children with autism

A new guideline for the nutrition of management gastrointestinal symptoms in children with autism spectrum disorders (ASD) provides a framework for clinicians to navigate frequently seen issues such as food selectivity, alternative diets and nutritional deficits. The expert panel was convened at Marcus Autism Center, an affiliate of Children's Healthcare of Atlanta and the resulting guideline was published online by the Journal of the Academy of Nutrition and Dietetics.

24 Jul 2015

Loss of dietary diversity contributes to rise in obesity, Type 2 diabetes and other diseases

A loss of dietary diversity during the past 50 years could be a contributing factor to the rise in obesity, Type 2 diabetes, gastrointestinal problems and other diseases, according to a lecture by Mark Heiman, vice president and chief scientific officer at MicroBiome Therapeutics, at IFT15: Where Science Feeds Innovation hosted by the Institute of Food Technologists in Chicago.

16 Jul 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA.

15 Jul 2015

Study provides insights into the cause of irritable bowel syndrome

A team comprised of scientists at VIB, KU Leuven and UZ Leuven has made significant progress in uncovering the connection between psychological factors and the immune system. Their findings are based on an investigation of a massive drinking water contamination incident in Belgium in 2010, and are now published in the leading international medical journal Gut.

2 Jul 2015

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States.

30 Jun 2015

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).

29 Jun 2015

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.

22 Jun 2015

Study identifies unique bacterial signature in people with systemic sclerosis

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with systemic sclerosis (SSc) have a unique bacterial signature in their colon, when compared with healthy people.

12 Jun 2015

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps that include the consistent use of experienced medical teams for a single type of surgery, preemptive antibiotics before the procedure, less reliance on potent opioids during recovery and urging patients to get out of bed and move around sooner can not only prevent infections, blood clots and other serious complications in people undergoing colorectal operations, but can also accelerate recovery and reduce cost of care, according to results of an ongoing program at The Johns Hopkins Hospital.

10 Jun 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

1 Jun 2015

Constipation News and Research

Latest Constipation News and Research

Researchers explore key factors to improve astronauts’ nutrition needs during space missions

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

New guidelines for nutrition of management GI symptoms in children with autism

Loss of dietary diversity contributes to rise in obesity, Type 2 diabetes and other diseases

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Study provides insights into the cause of irritable bowel syndrome

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Opioid offers pain relief for Parkinson’s patients

Study identifies unique bacterial signature in people with systemic sclerosis

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Helsinn's Akynzeo for CINV prevention receives EC approval

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Constipation News and Research

Latest Constipation News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in